

# Krebs Biochemicals & Industries Limited

CIN : L24110AP1991PLC103912



20<sup>th</sup> May, 2019

To,  
The Manager,  
Department of Corporate Relations,  
BSE Limited,  
P J Towers, Dalal Street,  
Fort, Mumbai- 400001.

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai- 400051.

Dear Sir/Madam,

**Sub: Submission of Quick Result.**

We refer to the above mentioned subject, we herewith submit to the Exchange the quick result for the quarter and year ended 31<sup>st</sup> March 2019 as approved by the Board of Directors at their meeting held on 20<sup>th</sup> May, 2019.

This is for the information and records of the Exchange, Please.

Thanking You,

Yours Faithfully,  
For **Krebs Biochemicals & Industries Limited**

  
**Haritha Varanasi**  
Company Secretary

Encl as above

**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No: 8, Banjara Hills, Hyderabad - 500 034

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2019**

(Rs. In lacs)

Sl.No	Particulars	Quarter Ended			Year Ended	
		31.03.2019 (Audited)	31.12.2018 (Unaudited)	31.03.2018 (Audited)	31.03.2019 (Audited)	31.03.2018 (Audited)
	<b>PART - 1</b>					
<b>1</b>	<b>Revenue from Operations</b>					
	a) Net Sales / Income from Operations	851.53	934.87	622.00	3,713.27	2,538.24
	b) Other Operating Income	319.53	199.48	398.55	1,062.53	839.67
<b>2</b>	<b>Other Income</b>	16.22	12.36	15.43	33.06	20.61
<b>3</b>	<b>Total Income from operations (1+2)</b>	<b>1,187.28</b>	<b>1,146.71</b>	<b>1,035.98</b>	<b>4,808.86</b>	<b>3,398.52</b>
<b>4</b>	<b>Expenses</b>					
	a) Cost of Material Consumed	435.18	704.38	534.07	2,099.43	1,712.36
	b) Changes in Inventories of Finished goods, Work-In-Progress	96.31	(109.05)	(171.30)	210.93	(441.83)
	c) Employee Benefits Expenses	387.80	412.63	533.61	1,493.70	1,201.05
	d) Finance Costs	189.73	145.94	142.14	623.80	516.52
	e) Depreciation and Amortisation Expense	118.11	107.37	109.40	440.23	414.97
	f) Other Manufacturing Expenses	380.68	440.85	519.21	1,579.60	1,320.57
	g) Other Expenses	111.43	90.99	86.56	373.41	335.94
	<b>Total Expenses (4)</b>	<b>1,719.24</b>	<b>1,793.11</b>	<b>1,753.69</b>	<b>6,821.10</b>	<b>5,059.58</b>
<b>5</b>	<b>Profit / (Loss) before exceptional items and tax (3±4)</b>	<b>(531.96)</b>	<b>(646.40)</b>	<b>(717.70)</b>	<b>(2,012.24)</b>	<b>(1,661.06)</b>
<b>6</b>	<b>Exceptional Items:</b>					
	a) Depletion in Value of Inventory	-	-	-	-	(95.35)
	b) Amounts Written Off/ written back	11.09	-	(0.89)	11.09	(0.89)
	c) Prior Period Income/(Expenditure)	-	-	(43.59)	-	(40.03)
	d) Profit on sale of Fixed Assets	-	-	14.83	-	14.83
<b>7</b>	<b>Profit / (Loss) before Tax (5 ± 6)</b>	<b>(520.87)</b>	<b>(646.40)</b>	<b>(747.35)</b>	<b>(2,001.15)</b>	<b>(1,782.49)</b>
<b>8</b>	<b>Tax Expense</b>					
	a) Current Tax					
	b) Deferred Tax					
<b>9</b>	<b>Profit / (Loss) for the period (7 ± 8)</b>	<b>(520.87)</b>	<b>(646.40)</b>	<b>(747.35)</b>	<b>(2,001.15)</b>	<b>(1,782.49)</b>
<b>10</b>	<b>Other Comprehensive Income (OCI)</b>					
	i) Items that will not be reclassified to profit or Loss	(5.09)	2.50	-	0.20	(33.24)
	ii) Income tax relating to items that will not be reclassified to profit or Loss	-	-	-	-	-
	iii) Items that will be reclassified to profit or Loss	(47.53)	(29.93)	(76.37)	(132.26)	(109.88)
	iv) Income tax relating to items that will be reclassified to profit or Loss	-	-	-	-	-
	<b>Total Other Comprehensive Income (Net of Tax)</b>	<b>(52.62)</b>	<b>(27.43)</b>	<b>(76.37)</b>	<b>(132.06)</b>	<b>(143.12)</b>
<b>11</b>	<b>Total Comprehensive Income for the period(9 ± 10) (Comprising Profit (Loss) and other Comprehensive Income for the period)</b>	<b>(573.49)</b>	<b>(673.83)</b>	<b>(823.71)</b>	<b>(2,133.22)</b>	<b>(1,925.61)</b>
<b>12</b>	<b>Paid-up Equity Share Capital (Face Value Rs. 10/- each)</b>	<b>1663.06</b>	<b>1374.43</b>	<b>1374.43</b>	<b>1663.06</b>	<b>1374.43</b>
<b>13</b>	<b>Other Equity excluding Revaluation Reserve</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(1,986.27)</b>	<b>(2,046.65)</b>
<b>14</b>	<b>Earning Per Share (of Rs.10/- each) (not Annualised)</b>					
	a) Basic	(3.45)	(4.90)	(5.99)	(12.83)	(14.01)
	b) Diluted	(4.16)	(4.90)	(5.99)	(15.46)	(14.01)
<b>15</b>	<b>Net Worth (including Retained Earnings)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>(1,428.91)</b>	<b>(1,777.92)</b>
	a) Debt Service Coverage Ratio	(1.57)	(2.05)	(2.53)	(1.46)	(1.39)
	b) Interest Service Coverage Ratio	(2.00)	(3.46)	(4.34)	(2.29)	(2.46)
	c) Debt Equity Ratio				(3.52)	(2.91)
	See accompanying notes to the Financial results					





**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

CIN:L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Anakapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corp Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

**Statement of Assets and Liabilities**


Rs. In Lacs

Particulars	As at 31.03.2019 Audited	As at 31.03.2018 Audited
<b>ASSETS</b>		
<b>Non Current Assets</b>		
(a)Property, Plant and Equipment	9,908.46	9,892.99
(b)Capital Work in Progress	163.45	218.94
(c)Other Intangible Assets	218.29	184.04
(d)Intangible assets under development	184.71	154.53
(e)Financial Assets	145.34	109.90
(f)Other Non Current Assets	518.58	303.33
<b>Total Non Current Assets</b>	<b>11,138.83</b>	<b>10,863.73</b>
<b>Current Assets</b>		
(a) Inventories	896.37	1,172.84
(b) Financial Assets		
(i) Trade Receivables	291.09	32.48
(ii) Cash & Cash Equivalents	1,731.89	41.84
(iii) Other Financial Assets	49.42	33.51
(c)Other Current Assets	128.90	443.19
<b>Total Current Assets</b>	<b>3,097.67</b>	<b>1,723.86</b>
<b>Total Assets</b>	<b>14,236.50</b>	<b>12,587.59</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share Capital	1,663.06	1,374.43
(b) Other Equity	(3,091.97)	(3,152.35)
<b>Total Equity</b>	<b>(1,428.91)</b>	<b>(1,777.92)</b>
<b>Liabilities</b>		
<b>Non Current Liabilities</b>		
(a)Financial Liabilities		
(i)Long Term Borrowings	5,022.71	5,166.17
(ii)Other Financial Liabilities	350.47	269.81
(b)Provisions	227.40	220.79
(c)Retirement benefit obligations	176.89	147.53
(d)Other Non Current Liabilities	4,401.79	4,333.04
<b>Total Non Current Liabilities</b>	<b>10,179.26</b>	<b>10,137.35</b>
<b>Current Liabilities</b>		
(a)Financial Liabilities		
(i)Borrowings	-	-
(ii)Trade Payables		
(a) Total outstanding dues of micro and small enterprises	321.79	-
(b) Total outstanding dues of creditors other than micro and small enterprises	1,824.49	1,776.00
(iii)Other Financial Liabilities	-	-
(b)Other Current Liabilities	3,197.23	2,326.71
(c)Provisions	65.59	52.95
(d)Retirement benefit obligations	77.04	72.49
<b>Total Current Liabilities</b>	<b>5,486.15</b>	<b>4,228.15</b>
<b>Total Equity and Liabilities</b>	<b>14,236.50</b>	<b>12,587.59</b>

Place: Hyderabad

Date: 20.05.2019



  
**AVINASH RAVI**  
 Managing Director

DIN: 01616152



**PAVULURI & Co.**  
**CHARTERED ACCOUNTANTS**


Plot No.48, Flat No.301,  
Micasa, Phase - I, Kavuri Hills,  
Hyderabad - 500 033.  
Ph : 040-2970 2638 / 2639 / 2640  
Email : pavuluriandco@gmail.com

**INDEPENDENT AUDITOR'S REPORT**

**TO THE BOARD OF DIRECTORS OF  
KREBS BIOCHEMICALS & INDUSTRIES LIMITED**

1. We have audited the accompanying Statement of Financial Results of **KREBS BIOCHEMICALS & INDUSTRIES LIMITED** ("the Company") for the quarter and year ended March 31, 2019 ("the Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement is the responsibility of the Company's Management and is approved by the Board of Directors. The Statement, as it relates to the quarter ended March 31, 2019, has been compiled from the related interim standalone financial statements prepared in accordance with Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34") and as it relates to the year ended March 31, 2019, has been compiled from the related annual financial statements prepared in accordance with Indian Accounting Standards, prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audits of such interim financial statements and annual financial statements.
3. We conducted our audits in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial controls relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal financial control. An audit also includes evaluating the appropriateness of the accounting







## PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,  
Micasa, Phase - I, Kavuri Hills,  
Hyderabad - 500 033.  
Ph : 040-2970 2638 / 2639 / 2640  
Email : pavuluriandco@gmail.com

policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
- (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
  - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the loss, total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2019.


For Pavuluri & Co  
Chartered Accountants  
(Firm's Regn No: 012194s)



CA.N.Rajesh

Partner

M.No: 223169



Place: Hyderabad

Date: May 20, 2019